Titan Partners Group, a division of American Capital Partners, has announced the launch of its equity research division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research analyst. In this role, Dr. Peaker will lead the firm’s healthcare sector research, with a focus on biotechnology.
Dr. Peaker brings 17 years of experience in healthcare equity research, most recently serving as managing director of biotechnology equity research at TD Cowen. Prior to that, he was an executive director at Oppenheimer & Co. and served as a biotechnology analyst at Cowen & Co. and Rodman & Renshaw, LLC. Dr. Recognized by multiple industry publications and associations as a top-ranked sector analyst, Dr. Peaker holds a Ph.D. in biophysics from Stanford University and a Bachelor of Science in physics and chemistry from the State University of New York.
“The launch of our research platform, spearheaded by Dr. Peaker, marks an important milestone in Titan’s growth,” remarked Jason Sands, co-founder and partner at Titan. “Our mission has always been to build a business around fundamentally strong and scientifically compelling stories. Dr. Peaker’s experience and reputation align perfectly with this objective.”
Ryan Konik, co-founder and partner at Titan, added, “Dr. Peaker’s technical background, combined with his sell-side research experience, makes him an exceptional fit for our platform. His addition underscores our continued commitment to the life sciences sector.”
